Ilsung Pharmaceuticals Co., Ltd. (003120.KS)
KRW 15970.0
(-0.19%)
KRW 15970.0
(-0.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -18.47 Billion KRW | -103.42% |
| 2022 | 145.29 Billion KRW | 2947.92% |
| 2021 | 1.56 Billion KRW | 70.36% |
| 2020 | 1.11 Billion KRW | -16.65% |
| 2019 | 1.82 Billion KRW | -51.94% |
| 2018 | 5.27 Billion KRW | -11.71% |
| 2017 | 5.81 Billion KRW | 42.56% |
| 2016 | 5.47 Billion KRW | -95.91% |
| 2015 | 5.35 Billion KRW | 1163.81% |
| 2014 | 5.24 Billion KRW | -29.0% |
| 2013 | 4.57 Billion KRW | -71.12% |
| 2012 | 51.66 Billion KRW | 2.52% |
| 2011 | 50.41 Billion KRW | 340.59% |
| 2010 | 12.51 Billion KRW | -40.5% |
| 2009 | 14.87 Billion KRW | -27.71% |
| 2008 | 52.28 Billion KRW | -3.45% |
| 2007 | 27.64 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -2.5 Billion KRW | 100.4% |
| 2024 Q2 | -2.16 Billion KRW | 118.71% |
| 2023 FY | - KRW | -103.42% |
| 2023 Q1 | 8.77 Billion KRW | 87.17% |
| 2023 Q4 | -463.94 Million KRW | -106.17% |
| 2023 Q3 | 7.51 Billion KRW | -30.3% |
| 2023 Q2 | 10.78 Billion KRW | 22.92% |
| 2022 Q1 | 2.03 Billion KRW | 98.02% |
| 2022 Q3 | 5.06 Billion KRW | -96.15% |
| 2022 Q4 | 4.68 Billion KRW | -7.47% |
| 2022 Q2 | 131.52 Billion KRW | 6364.19% |
| 2022 FY | - KRW | 2947.92% |
| 2021 Q4 | 1.02 Billion KRW | -39.15% |
| 2021 FY | - KRW | 70.36% |
| 2021 Q1 | 1.16 Billion KRW | 480.23% |
| 2021 Q2 | 822.58 Million KRW | -29.28% |
| 2021 Q3 | 1.68 Billion KRW | 105.3% |
| 2020 Q1 | 1.64 Billion KRW | 62.24% |
| 2020 Q3 | 440.81 Million KRW | -6.72% |
| 2020 Q2 | 472.56 Million KRW | -71.3% |
| 2020 FY | - KRW | -16.65% |
| 2020 Q4 | 200.47 Million KRW | -54.52% |
| 2019 Q3 | 502.49 Million KRW | 112.56% |
| 2019 FY | - KRW | -51.94% |
| 2019 Q1 | -2.96 Million KRW | -100.1% |
| 2019 Q4 | 1.01 Billion KRW | 101.94% |
| 2019 Q2 | -3.99 Billion KRW | -134966.63% |
| 2018 Q2 | 945.53 Million KRW | -59.22% |
| 2018 Q1 | 2.31 Billion KRW | 98.72% |
| 2018 FY | - KRW | -11.71% |
| 2018 Q3 | 487.28 Million KRW | -48.46% |
| 2018 Q4 | 3.04 Billion KRW | 524.94% |
| 2017 Q1 | 3.36 Billion KRW | 192.21% |
| 2017 Q4 | 1.16 Billion KRW | -16.23% |
| 2017 Q3 | 1.39 Billion KRW | 95.31% |
| 2017 Q2 | 713.13 Million KRW | -78.79% |
| 2017 FY | - KRW | 42.56% |
| 2016 Q1 | 1.21 Billion KRW | -99.03% |
| 2016 FY | - KRW | -95.91% |
| 2016 Q4 | 1.15 Billion KRW | -27.13% |
| 2016 Q3 | 1.57 Billion KRW | 0.94% |
| 2016 Q2 | 1.56 Billion KRW | 28.41% |
| 2015 FY | - KRW | 1163.81% |
| 2015 Q4 | 125.79 Billion KRW | 11311.57% |
| 2015 Q3 | 1.1 Billion KRW | -56.17% |
| 2015 Q2 | 2.51 Billion KRW | -40.67% |
| 2015 Q1 | 4.23 Billion KRW | -36.3% |
| 2014 FY | - KRW | -29.0% |
| 2014 Q1 | 1.9 Billion KRW | 86.02% |
| 2014 Q4 | 6.65 Billion KRW | 367.72% |
| 2014 Q3 | 1.42 Billion KRW | 129.6% |
| 2014 Q2 | 619.75 Million KRW | -67.43% |
| 2013 Q3 | 1.45 Billion KRW | -55.22% |
| 2013 Q4 | 1.02 Billion KRW | -29.94% |
| 2013 FY | - KRW | -71.12% |
| 2013 Q1 | 9.18 Billion KRW | -40.22% |
| 2013 Q2 | 3.26 Billion KRW | -64.51% |
| 2012 Q4 | 15.36 Billion KRW | 271.21% |
| 2012 Q2 | 11.67 Billion KRW | -43.05% |
| 2012 FY | - KRW | 2.52% |
| 2012 Q3 | 4.13 Billion KRW | -64.55% |
| 2012 Q1 | 20.5 Billion KRW | -50.12% |
| 2011 Q4 | 41.1 Billion KRW | 2325.65% |
| 2011 Q1 | 5.02 Billion KRW | 483.79% |
| 2011 Q2 | 2.58 Billion KRW | -48.56% |
| 2011 FY | - KRW | 340.59% |
| 2011 Q3 | 1.69 Billion KRW | -34.49% |
| 2010 FY | - KRW | -40.5% |
| 2010 Q4 | 861.37 Million KRW | -60.24% |
| 2010 Q3 | 2.16 Billion KRW | -2.23% |
| 2010 Q2 | 2.21 Billion KRW | -64.26% |
| 2010 Q1 | 6.19 Billion KRW | 26.5% |
| 2009 Q2 | 5.21 Billion KRW | -1.76% |
| 2009 Q3 | 3.81 Billion KRW | -26.88% |
| 2009 Q1 | 5.3 Billion KRW | 15.61% |
| 2009 Q4 | 4.9 Billion KRW | 28.58% |
| 2009 FY | - KRW | -27.71% |
| 2008 Q4 | 4.58 Billion KRW | -24.95% |
| 2008 Q3 | 6.11 Billion KRW | 3.71% |
| 2008 Q2 | 5.89 Billion KRW | -41.04% |
| 2008 Q1 | 10 Billion KRW | 87.5% |
| 2008 FY | - KRW | -3.45% |
| 2007 FY | - KRW | 0.0% |
| 2007 Q4 | 5.33 Billion KRW | -17.35% |
| 2007 Q3 | 6.45 Billion KRW | -13.96% |
| 2007 Q2 | 7.49 Billion KRW | -10.98% |
| 2007 Q1 | 8.42 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 480.209% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 113.067% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 71.154% |
| HANDOK Inc. | 35.06 Billion KRW | 152.676% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | -1682.005% |
| Yuhan Corporation | 127.43 Billion KRW | 114.495% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 149.231% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 14.828% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 105.713% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 470.153% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 222.182% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | 639.958% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | 508.091% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 152.053% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 480.209% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 381.799% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 62.526% |
| JW Holdings Corporation | 187.88 Billion KRW | 109.831% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 63.942% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 106.513% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 120.704% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 50.166% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 239.836% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 256.172% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 199.019% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 480.209% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 133.602% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 111.201% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 120.704% |
| Yuhan Corporation | 127.43 Billion KRW | 114.495% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 155.179% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 341.467% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 123.981% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 120.704% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 150.422% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 126.097% |
| CKD Bio Corp. | -1.63 Billion KRW | -1032.932% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 137.097% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 156.729% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 150.181% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 50.166% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 129.657% |
| Boryung Corporation | 114.28 Billion KRW | 116.163% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 39.572% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 222.182% |
| JW Lifescience Corporation | 50.82 Billion KRW | 136.341% |